ABSTRACT
Vaccines save millions of lives from infectious diseases caused by viruses and bacteria. As the world awaits safe and effective COVID-19 vaccines, we celebrate the progresses made and highlight challenges ahead in vaccines and the science behind them.
Subject(s)
Communicable Disease Control , Communicable Diseases/immunology , Vaccines/immunology , Adjuvants, Immunologic/administration & dosage , COVID-19 , COVID-19 Vaccines , Clinical Trials as Topic , Communicable Diseases/microbiology , Communicable Diseases/parasitology , Communicable Diseases/virology , Coronavirus Infections/etiology , Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Coronavirus Infections/virology , Drug Utilization , Humans , Immunity, Herd , Pandemics/prevention & control , Patient Acceptance of Health Care , Pneumonia, Viral/immunology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/virology , Vaccination , Vaccines/administration & dosage , Viral Vaccines/chemistry , Viral Vaccines/immunologyABSTRACT
The mammalian inflammatory response is a rapid and complex physiological reaction to noxious stimuli including microbial pathogens. Although inflammation plays a valuable role in combating infection, its dysregulation often occurs in people and can cause a variety of pathologies, ranging from chronic inflammation, to autoimmunity, to cancer. In recent years, our understanding of both the cellular and molecular networks that regulate inflammation has improved dramatically. Although much of the focus has been on the study of protein regulators of inflammation, recent evidence also points to a critical role for a specific class of noncoding RNAs, called microRNAs (miRNAs), in managing certain features of the inflammatory process. In this review, we discuss recent advances in our understanding of miRNAs and their connection to inflammatory responses. Additionally, we consider the link between perturbations in miRNA levels and the onset of human inflammatory diseases.
Subject(s)
Inflammation/genetics , MicroRNAs/genetics , Adaptive Immunity/genetics , Animals , Autoimmunity/genetics , Communicable Diseases/genetics , Communicable Diseases/immunology , Hematologic Neoplasms/genetics , Hematologic Neoplasms/immunology , Humans , Immunity, Innate/genetics , Inflammation/immunologyABSTRACT
The mammalian alimentary tract harbors hundreds of species of commensal microorganisms (microbiota) that intimately interact with the host and provide it with genetic, metabolic, and immunological attributes. Recent reports have indicated that the microbiota composition and its collective genomes (microbiome) are major factors in predetermining the type and robustness of mucosal immune responses. In this review, we discuss the recent advances in our understanding of host-microbiota interactions and their effect on the health and disease susceptibility of the host.
Subject(s)
Communicable Diseases/immunology , Communicable Diseases/microbiology , Inflammation/immunology , Inflammation/microbiology , Metagenome/immunology , Adaptive Immunity , Animals , Host-Pathogen Interactions/immunology , Humans , Immunity, Innate , Immunity, Mucosal , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Lymphocytes/immunology , Lymphocytes/metabolism , Signal TransductionABSTRACT
A fundamental concept in immunology is that the innate immune system initiates or instructs downstream adaptive immune responses. Inflammasomes are central players in innate immunity to pathogens, but how inflammasomes shape adaptive immunity is complex and relatively poorly understood. Here we highlight recent work on the interplay between inflammasomes and adaptive immunity. We address how inflammasome-dependent release of cytokines and antigen activates, shapes or even inhibits adaptive immune responses. We consider how distinct tissue or cellular contexts may alter the effects of inflammasome activation on adaptive immunity and how this contributes to beneficial or detrimental outcomes in infectious diseases, cancer and autoimmunity. We aspire to provide a framework for thinking about inflammasomes and their connection to the adaptive immune response.
Subject(s)
Adaptive Immunity , Antigens/metabolism , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Cytokines/metabolism , Inflammasomes/metabolism , Animals , Antigens/immunology , Autoimmune Diseases/immunology , Autoimmune Diseases/metabolism , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Communicable Diseases/immunology , Communicable Diseases/metabolism , Cytokines/immunology , Humans , Inflammasomes/immunology , Lymphocyte Activation , Neoplasms/immunology , Neoplasms/metabolism , Pyroptosis , Signal Transduction , VaccinationABSTRACT
CD8+ T cells are critical mediators of cytotoxic effector function in infection, cancer and autoimmunity. In cancer and chronic viral infection, CD8+ T cells undergo a progressive loss of cytokine production and cytotoxicity, a state termed T cell exhaustion. In autoimmunity, autoreactive CD8+ T cells retain the capacity to effectively mediate the destruction of host tissues. Although the clinical outcome differs in each context, CD8+ T cells are chronically exposed to antigen in all three. These chronically stimulated CD8+ T cells share some common phenotypic features, as well as transcriptional and epigenetic programming, across disease contexts. A better understanding of these CD8+ T cell states may reveal novel strategies to augment clearance of chronic viral infection and cancer and to mitigate self-reactivity leading to tissue damage in autoimmunity.
Subject(s)
Autoimmune Diseases/immunology , Autoimmunity , CD8-Positive T-Lymphocytes/immunology , Communicable Diseases/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Neoplasms/immunology , Animals , Autoimmune Diseases/genetics , Autoimmune Diseases/metabolism , B7-H1 Antigen/immunology , B7-H1 Antigen/metabolism , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/metabolism , Chronic Disease , Communicable Diseases/genetics , Communicable Diseases/metabolism , Cytokines/immunology , Cytokines/metabolism , Epigenesis, Genetic , Humans , Immune Checkpoint Inhibitors/therapeutic use , Lymphocytes, Tumor-Infiltrating/drug effects , Lymphocytes, Tumor-Infiltrating/metabolism , Neoplasms/drug therapy , Neoplasms/genetics , Neoplasms/metabolism , Phenotype , Programmed Cell Death 1 Receptor/immunology , Programmed Cell Death 1 Receptor/metabolism , Receptors, Antigen, T-Cell/immunology , Receptors, Antigen, T-Cell/metabolism , Signal TransductionABSTRACT
Regardless of microbial virulence (i.e., the global infection-fatality ratio), age generally drives the prevalence of death from infection in unvaccinated humans. Four mortality patterns are recognized: the common U- and L-shaped curves of endemic infections and the unique W- and J-shaped curves of pandemic infections. We suggest that these patterns result from different sets of human genetic and immunological determinants. In this model, it is the interplay between (1) monogenic genotypes affecting immunity to primary infection that preferentially manifest early in life and related genotypes or their phenocopies, including auto-antibodies, which manifest later in life and (2) the occurrence and persistence of adaptive, acquired immunity to primary or cross-reactive infections, which shapes the age-dependent pattern of human deaths from infection.
Subject(s)
Communicable Diseases , Humans , Age Factors , Communicable Diseases/mortality , Communicable Diseases/immunology , Communicable Diseases/epidemiology , Adaptive Immunity/genetics , Aging/immunology , Aging/genetics , PandemicsABSTRACT
Better understanding of the biology of infectious agents and of the mechanisms of efficient immune responses advances strategies to achieve protection against infectious diseases.
Subject(s)
Communicable Diseases/immunology , Animals , HumansABSTRACT
Biologists, physicians and immunologists have contributed to the understanding of the cellular participants and biological pathways involved in inflammation. Here, we provide a general guide to the cellular and humoral contributors to inflammation as well as to the pathways that characterize inflammation in specific organs and tissues.
Subject(s)
Communicable Diseases/immunology , Immunity, Cellular/immunology , Immunity, Humoral/immunology , Inflammation/immunology , Acute Disease , Chronic Disease , HumansABSTRACT
Helping B cells and antibody responses is a major function of CD4+ T cells. It has been 10 years since the publication of Bcl6 as the lineage-defining transcription factor for T follicular helper (Tfh) differentiation and the requirement of Tfh cells as the specialized subset of CD4+ T cells needed for germinal centers (the microanatomical sites of B cell mutation and antibody affinity maturation) and related B cell responses. A great deal has been learned about Tfh cells in the past 10 years, particularly regarding their roles in a surprising range of diseases. Advances in the understanding of Tfh cell differentiation and function are discussed, as are the understanding of Tfh cells in infectious diseases, vaccines, autoimmune diseases, allergies, atherosclerosis, organ transplants, and cancer. This includes discussion of Tfh cells in the human immune system. Based on the discoveries to date, the next decade of Tfh research surely holds many more surprises. VIDEO ABSTRACT.
Subject(s)
B-Lymphocytes/immunology , Germinal Center/immunology , T-Lymphocytes, Helper-Inducer/cytology , T-Lymphocytes, Helper-Inducer/immunology , Atherosclerosis/immunology , Autoimmune Diseases/immunology , Cell Differentiation/immunology , Communicable Diseases/immunology , Humans , Hypersensitivity/immunology , Proto-Oncogene Proteins c-bcl-6/metabolismABSTRACT
Although a great public heath success, vaccines provide suboptimal protection in some patient populations and are not available to protect against many infectious diseases. Insights from innate immunity research have led to a better understanding of how existing vaccines work and have informed vaccine development. New adjuvants and delivery systems are being designed based upon their capacity to stimulate innate immune sensors and target antigens to dendritic cells, the cells responsible for initiating adaptive immune responses. Incorporating these adjuvants and delivery systems in vaccines can beneficially alter the quantitative and qualitative nature of the adaptive immune response, resulting in enhanced protection.
Subject(s)
Immunity, Innate , Vaccines/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Communicable Disease Control , Communicable Diseases/immunology , Empiricism , Humans , Vaccines/therapeutic useSubject(s)
Autoimmune Diseases/prevention & control , Communicable Disease Control/methods , Hypersensitivity/prevention & control , Immunotherapy/methods , Neoplasms/prevention & control , Translational Research, Biomedical/trends , Animals , Antibodies, Monoclonal/biosynthesis , Antibodies, Monoclonal/therapeutic use , Antigens/chemistry , Antigens/genetics , Antigens/immunology , Autoimmune Diseases/immunology , Bacterial Vaccines/administration & dosage , Bacterial Vaccines/biosynthesis , Cancer Vaccines/administration & dosage , Cancer Vaccines/biosynthesis , Communicable Diseases/immunology , Communicable Diseases/pathology , Cytokines/agonists , Cytokines/antagonists & inhibitors , Cytokines/genetics , Cytokines/immunology , Fungal Vaccines/administration & dosage , Fungal Vaccines/biosynthesis , Humans , Hypersensitivity/immunology , Immunoassay/methods , Neoplasms/immunology , Viral Vaccines/administration & dosage , Viral Vaccines/biosynthesisABSTRACT
Infections in the first year of life are common and often severe. The newborn host demonstrates both quantitative and qualitative differences to the adult in nearly all aspects of immunity, which at least partially explain the increased susceptibility to infection. Here we discuss how differences in susceptibility to infection result not out of a state of immaturity, but rather reflect adaptation to the particular demands placed on the immune system in early life. We review the mechanisms underlying host defense in the very young, and discuss how specific developmental demands increase the risk of particular infectious diseases. In this context, we discuss how this plasticity, i.e. the capacity to adapt to demands encountered in early life, also provides the potential to leverage protection of the young against infection and disease through a number of interventions.
Subject(s)
Communicable Diseases/immunology , Disease Susceptibility/immunology , Immune System/growth & development , Infant, Newborn/immunology , Infant , Animals , Humans , Immune System/immunologyABSTRACT
The Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome has been the most distinctive polymer protein complex. After recognizing the endogenous and exogenous danger signals, NLRP3 can cause inflammation by pyroptosis and secretion of mature, bioactive forms of IL-1ß and IL-18. The NLRP3 inflammasome is essential in the genesis and progression of infectious illnesses. Herein, we provide a comprehensive review of the NLRP3 inflammasome in infectious diseases, focusing on its two-sided effects. As an essential part of host defense with a protective impact, abnormal NLRP3 inflammasome activation, however, result in a systemic high inflammatory response, leading to subsequent damage. In addition, scientific evidence of small molecules, biologics, and phytochemicals acting on the NLRP3 inflammasome has been reviewed. We believe that the NLRP3 inflammasome helps us understand the pathological mechanism of different stages of infectious diseases and that inhibitors targeting the NLRP3 inflammasome will become a new and valuable research direction for the treatment of infectious diseases.
Subject(s)
Communicable Diseases , Inflammasomes , NLR Family, Pyrin Domain-Containing 3 Protein , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/immunology , Humans , Inflammasomes/immunology , Inflammasomes/metabolism , Animals , Communicable Diseases/immunology , Communicable Diseases/metabolism , Inflammation/immunology , Interleukin-1beta/metabolism , Interleukin-1beta/immunologyABSTRACT
The derivation of induced pluripotent stem cells (iPSCs) over a decade ago sparked widespread enthusiasm for the development of new models of human disease, enhanced platforms for drug discovery and more widespread use of autologous cell-based therapy. Early studies using directed differentiation of iPSCs frequently uncovered cell-level phenotypes in monogenic diseases, but translation to tissue-level and organ-level diseases has required development of more complex, 3D, multicellular systems. Organoids and human-rodent chimaeras more accurately mirror the diverse cellular ecosystems of complex tissues and are being applied to iPSC disease models to recapitulate the pathobiology of a broad spectrum of human maladies, including infectious diseases, genetic disorders and cancer.
Subject(s)
Communicable Diseases/therapy , Genetic Diseases, Inborn/therapy , Induced Pluripotent Stem Cells/cytology , Models, Biological , Neoplasms/therapy , Tissue Engineering/methods , Animals , Cell Differentiation , Cell Lineage/genetics , Cell Lineage/immunology , Chimera/genetics , Chimera/immunology , Communicable Diseases/genetics , Communicable Diseases/immunology , Communicable Diseases/pathology , Drug Discovery/methods , Genetic Diseases, Inborn/genetics , Genetic Diseases, Inborn/immunology , Genetic Diseases, Inborn/pathology , Genetic Therapy/methods , Humans , Induced Pluripotent Stem Cells/immunology , Induced Pluripotent Stem Cells/transplantation , Models, Animal , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/pathology , Organoids/cytology , Organoids/drug effects , Organoids/immunology , Tissue Transplantation/methods , Transplantation, HeterologousABSTRACT
SignificanceUsing SARS-CoV-2 as a relevant case study for infectious disease, we investigate the structure-function relationships that dictate antiviral spherical nucleic acid (SNA) vaccine efficacy. We show that the SNA architecture can be rapidly employed to target COVID-19 through incorporation of the receptor-binding domain, and that the resulting vaccine potently activates human cells in vitro and mice in vivo. Furthermore, when challenged with a lethal viral infection, only mice treated with the SNA vaccine survived. Taken together, this work underscores the importance of rational vaccine design for infectious disease to yield vaccines that elicit more potent immune responses to effectively fight disease.
Subject(s)
Communicable Disease Control , Nucleic Acids/immunology , Vaccines, DNA/immunology , Animals , Biotechnology , COVID-19/prevention & control , Communicable Disease Control/methods , Communicable Diseases/etiology , Communicable Diseases/immunology , Humans , Nucleic Acids/chemistry , SARS-CoV-2/immunology , Vaccine Development , Vaccines, DNA/genetics , Viral Vaccines/genetics , Viral Vaccines/immunologyABSTRACT
Toll-like receptors (TLRs) are key initiators of the innate immune response and promote adaptive immunity. Much has been learned about the role of TLRs in human immunity from studies linking TLR genetic variation with disease. First, monogenic disorders associated with complete deficiency in certain TLR pathways, such as MyD88-IRAK4 or TLR3-Unc93b-TRIF-TRAF3, have demonstrated the specific roles of these pathways in host defense against pyogenic bacteria and herpesviruses, respectively. Second, common polymorphisms in genes encoding several TLRs and associated genes have been associated with both infectious and autoimmune diseases. The study of genetic variation in TLRs in various populations combined with information on infection has demonstrated complex interaction between genetic variation in TLRs and environmental factors. This interaction explains the differences in the effect of TLR polymorphisms on susceptibility to infection and autoimmune disease in various populations.
Subject(s)
Communicable Diseases/genetics , Communicable Diseases/immunology , Toll-Like Receptors/genetics , Toll-Like Receptors/immunology , Disease Susceptibility , Genetic Variation , Humans , Immunity, Innate/genetics , Immunity, Innate/immunology , Models, Molecular , Polymorphism, Single Nucleotide , Toll-Like Receptors/chemistryABSTRACT
In epidemics, waning immunity is common after infection or vaccination of individuals. Immunity levels are highly heterogeneous and dynamic. This work presents an immuno-epidemiological model that captures the fundamental dynamic features of immunity acquisition and wane after infection or vaccination and analyzes mathematically its dynamical properties. The model consists of a system of first order partial differential equations, involving nonlinear integral terms and different transfer velocities. Structurally, the equation may be interpreted as a Fokker-Planck equation for a piecewise deterministic process. However, unlike the usual models, our equation involves nonlocal effects, representing the infectivity of the whole environment. This, together with the presence of different transfer velocities, makes the proved existence of a solution novel and nontrivial. In addition, the asymptotic behavior of the model is analyzed based on the obtained qualitative properties of the solution. An optimal control problem with objective function including the total number of deaths and costs of vaccination is explored. Numerical results describe the dynamic relationship between contact rates and optimal solutions. The approach can contribute to the understanding of the dynamics of immune responses at population level and may guide public health policies.
Subject(s)
Communicable Diseases , Mathematical Concepts , Models, Immunological , Vaccination , Humans , Vaccination/statistics & numerical data , Communicable Diseases/immunology , Communicable Diseases/epidemiology , Communicable Diseases/transmission , Computer Simulation , Epidemics/statistics & numerical data , Epidemiological ModelsABSTRACT
Nanobodies are the smallest known antigen-binding molecules to date. Their small size, good tissue penetration, high stability and solubility, ease of expression, refolding ability, and negligible immunogenicity in the human body have granted them excellence over conventional antibodies. Those exceptional attributes of nanobodies make them promising candidates for various applications in biotechnology, medicine, protein engineering, structural biology, food, and agriculture. This review presents an overview of their structure, development methods, advantages, possible challenges, and applications with special emphasis on infectious diseases-related ones. A showcase of how nanobodies can be harnessed for applications including neutralization of viruses and combating antibiotic-resistant bacteria is detailed. Overall, the impact of nanobodies in vaccine design, rapid diagnostics, and targeted therapies, besides exploring their role in deciphering microbial structures and virulence mechanisms are highlighted. Indeed, nanobodies are reshaping the future of infectious disease prevention and treatment.
Subject(s)
Communicable Diseases , Single-Domain Antibodies , Single-Domain Antibodies/immunology , Humans , Communicable Diseases/immunology , Communicable Diseases/therapy , Animals , Biotechnology/methods , Protein Engineering/methodsABSTRACT
Respiratory viruses cause mild to severe diseases in humans every year, constituting a major public health problem. Characterizing the pathogenesis in physiologically relevant models is crucial for developing efficient vaccines and therapeutics. Here, we show that lung organoids derived from human primary or lung tumor tissue maintain the cellular composition and characteristics of the original tissue. Moreover, we show that these organoids sustain viral replication with particular infection foci formation, and they activate the expression of interferon-associated and proinflammatory genes responsible for mediating a robust innate immune response. All together, we show that three-dimensional (3D) lung organoids constitute a relevant platform to model diseases and enable the development of drug screenings. IMPORTANCE Three-dimensional (3D) human lung organoids reflect the native cell composition of the lung as well as its physiological properties. Human 3D lung organoids offer ideal conditions, such as timely availability in large quantities and high physiological relevance for reassessment and prediction of disease outbreaks of respiratory pathogens and pathogens that use the lung as a primary entry portal. Human lung organoids can be used in basic research and diagnostic settings as early warning cell culture systems and also serve as a relevant platform for modeling infectious diseases and drug development. They can be used to characterize pathogens and analyze the influence of infection on, for example, immunological parameters, such as the expression of interferon-associated and proinflammatory genes in the context of cancer. In our study, we found that cancer-derived lung organoids were more sensitive to influenza A virus infection than those derived from healthy tissue and demonstrated a decreased innate immune response.
Subject(s)
Lung , Organ Culture Techniques , Organoids , Communicable Diseases/diagnosis , Communicable Diseases/immunology , Humans , Immunity, Innate , Interferons , Lung/pathology , Organ Culture Techniques/methods , Organoids/immunology , Organoids/virologyABSTRACT
The eponymous member of the interferon regulatory factor (IRF) family, IRF1, was originally identified as a nuclear factor that binds and activates the promoters of type I interferon genes. However, subsequent studies using genetic knockouts or RNAi-mediated depletion of IRF1 provide a much broader view, linking IRF1 to a wide range of functions in protection against invading pathogens. Conserved throughout vertebrate evolution, IRF1 has been shown in recent years to mediate constitutive as well as inducible host defenses against a variety of viruses. Fine-tuning of these ancient IRF1-mediated host defenses, and countering strategies by pathogens to disarm IRF1, play crucial roles in pathogenesis and determining the outcome of infection.